

Chapter 6

Host Defense Peptides and the Eicosanoid Cascade

Min Wan, Xiao Tang and Jesper Z. Haeggström

Abstract Host defense peptides (HDPs) and eicosanoids are two important families in host defense and inflammation. Most of the naturally occurring HDPs are cationic and amphipathic short polypeptides with typical length between 15 and 40 amino acid residues. HDPs not only possess potent antimicrobial activity against a variety of pathogens, they are also widely recognized for their multifunctional roles in both the innate and adaptive immune responses. On the other hand, arachidonic acid-derived eicosanoids, including prostaglandins, thromboxanes, leukotrienes and lipoxins, are small lipid molecules with a 20-carbon backbone, which possess potent biological properties and participate in regulation of physiological and pathophysiological processes. In this article, we discuss the biosynthesis and functions of eicosanoids with emphasis on the roles of eicosanoids in host defense and regulation of HDP production. Moreover, we review how HDPs regulate eicosanoid metabolism and conclude that there are positive feedback circuits between HDP and eicosanoid signaling with implications for certain pathological conditions, such as infection and allergy.

6.1 Introduction

Arachidonic acid (AA) is released from phospholipids by phospholipases A₂ (PLA₂), and metabolism of AA leads to several families of lipid mediators collectively known as eicosanoids, including prostaglandins (PGs), thromboxanes, leukotrienes (LTs), and lipoxins (LXs), along two major pathways, the lipoxygenase (LOX) and the cyclooxygenase (COX) pathways (Haeggstrom and Funk

M. Wan (✉) · X. Tang · J.Z. Haeggström (✉)
Department of Medical Biochemistry and Biophysics,
Division of Physiological Chemistry II, Karolinska Institutet,
SE-17177 Stockholm, Sweden
e-mail: min.wan@ki.se

J.Z. Haeggström
e-mail: jesper.haeggstrom@ki.se

2011). Eicosanoids are secreted and act locally in an autocrine or paracrine fashion through interaction with specific G-protein coupled receptors (GPCR) to exert their biological effects (Back et al. 2011; Woodward et al. 2011; Serhan 2014). They possess potent biological activities and are involved in fever, pain, maintenance of normal hemostasis, regulation of blood pressure, renal function, and reproduction as well as host defense (Haeggstrom and Funk 2011).

Host defense peptides (HDPs), also known as antimicrobial peptides (AMPs), are evolutionarily conserved molecules of the innate immune system. Their widespread distribution throughout the animal and plant kingdoms suggests that HDPs have served a fundamental role in the successful evolution of complex multicellular organisms (Zasloff 2002). They are not only important molecules in host defense against a very broad spectrum of microorganisms, such as gram negative and gram positive bacteria, fungi, parasites, and viruses, via various mechanisms of action, but also possess diverse immunomodulatory capabilities (Mansour et al. 2014).

Several studies have indicated that inhibition of eicosanoid biosynthesis lethally impairs insect immune reactions (Stanley-Samuels et al. 1991) and also that eicosanoids play an important role in regulating innate immunity and host defense of mammals (Peters-Golden et al. 2005; Dennis and Norris 2015). The first suggestion that eicosanoids are involved in signaling pathways that lead to HDP production came from a study demonstrating that an eicosanoid biosynthesis inhibitor suppressed two HDP gene expressions in response to bacterial challenge in the fat body of the silkworm, *Bombyx mori* (Morishima et al. 1997). Accumulating evidence from the studies on insects suggested a direct induction of HDPs by AA (Morishima et al. 1997; Sun and Faye 1995), and also a direct functional link between eicosanoids and the production of HDPs induced by LPS (Yajima et al. 2003) or peptidoglycan (Morishima et al. 1997). Interestingly, the studies from our research group and others have also suggested positive feedback loops between eicosanoids and HDP production in mammalian leukocytes (Wan et al. 2011; Sun et al. 2013; Kanda et al. 2010; Bernard and Gallo 2010; Niyonsaba et al. 2001; Kase et al. 2009; Chen et al. 2007).

In this chapter, we will discuss the role of eicosanoids in host defense, and how HDPs and eicosanoids, two important families of innate immunity interact and cooperate to regulate the innate immunity and control infections.

6.2 Eicosanoids in Host Defense

PLA₂ enzymes are crucial for increasing the levels of free AA for eicosanoid biosynthesis under most physiological conditions, but particularly following inflammatory cell activation (Dennis and Norris 2015). Three members of the PLA₂ superfamily have been implicated most strongly in cellular eicosanoid production: cytosolic calcium-dependent PLA₂ (cPLA₂), cytosolic calcium independent PLA₂ (iPLA₂) and secreted PLA₂ (sPLA₂) (Dennis and Norris 2015). Among them, cPLA_{2α} is the only PLA₂ that exhibits preference for hydrolysis of AA from

phospholipid substrates that occurs in cells stimulated with diverse agonists (Leslie 2015). The observation that mice lacking cPLA₂ are profoundly depleted of all eicosanoids indicates that this enzyme is indispensable for the liberation of AA in vivo (Fujishima et al. 1999). Because AA is the precursor of eicosanoids, it is generally accepted that cPLA_{2α} plays a major role in inflammatory diseases (Dennis et al. 2011).

Early studies on insects demonstrated that eicosanoids play an important role in bacterial infection by using PLA₂ inhibitor, and the functions suppressed by PLA₂ inhibitor can be rescued by adding exogenous AA (Stanley-Samuelson et al. 1991, 1997; Yajima et al. 2003; Miller et al. 1994). Subsequent studies further showed that AA and eicosanoids promote HDP expression in insects (Morishima et al. 1997; Sun and Faye 1995; Yajima et al. 2003; Hwang et al. 2013). Studies in humans and mammals demonstrated that eicosanoids affect the immune response by modulating cellular differentiation, migration, phagocytosis, and cytokine/chemokine production, and also play an important role in connecting innate and adaptive immunity by acting on cells of both systems (Harizi and Gualde 2005). It has been reported that zymosan and *Candida albicans* induce cPLA₂ activation and eicosanoid production in macrophages via different signaling mechanisms (Gijon et al. 2000; Suram et al. 2006, 2010). Moreover, a recent report investigated the functional consequences of cPLA_{2α} activation and the effect of endogenously produced eicosanoids on gene expression in response to *C. albicans* by comparing cPLA_{2α}^{+/+} and cPLA_{2α}^{-/-} resident mouse peritoneal macrophages (RPM), and the results revealed that *C. albicans* killing was impaired in cPLA_{2α} deficient RPM, and *C. albicans*-stimulated cPLA_{2α} activation and the early production of prostanoids promote an autocrine pathway in RPM that affects the expression of genes involved in host defense to dampen inflammation (Suram et al. 2013). In addition, it has also been shown that AA stimulates human neutrophils to release HDPs to strongly impair bacterial growth (Chouinard et al. 2013). Interestingly, evidence has been provided that eicosanoids are involved in lactose and phenylbutyrate (PBA)-induced human cathelicidin expression in human epithelial cell line HT-29 since a PLA₂ inhibitor significantly suppressed lactose/PBA-induced peptide expression (Cederlund et al. 2014).

We will discuss more details on LTs, PGs and LXs in host defense and infections.

6.2.1 Prostanoids

Prostanoids are lipid mediators derived from AA via the COX pathway. COX exists as two isoforms referred to as COX-1 and COX-2. COX-1 is expressed constitutively in most tissues, whereas COX-2 is not detectable in most normal tissues or resting immune cells, but its expression can be induced by factors such as endotoxins, cytokines, growth factors, and carcinogens (Smith et al. 2011). COX enzymes convert AA to the unstable endoperoxide PGH₂, which can be




Fig. 6.1 Biosynthesis of prostanoinds. Arachidonic acid (AA) can be metabolized by cyclooxygenase (COX) isoforms known as COX-1 and COX-2. Unlike COX-1, which is constitutively expressed in most tissues and cells, COX-2 remains at low expression in resting cells. However, COX-2 can be activated by factors such as endotoxins, cytokines, growth factors and carcinogens. COX isozymes convert AA to the unstable endoperoxide prostaglandin (PG)H₂, which is further metabolized to PGE₂, PGD₂, PGF_{2α}, PGI₂ (prostacyclin), and thromboxane A₂ (TXA₂) by specific terminal synthases, in a cell-type restricted fashion. PGs exert their functions via specific G-protein coupled receptors (GPCR), i.e., EPs, DPs, FP, IP and TPs in an autocrine or paracrine manner

metabolized by the actions of specific terminal synthases that are expressed in a cell type-selective fashion to produce PGE₂, PGD₂, PGF_{2α}, PGI₂ (prostacyclin), and thromboxane A₂ (TXA₂), which are collectively called prostanoinds (Hirata and Narumiya 2012). The biosynthesis of prostanoinds is summarized in Fig. 6.1.

PGE₂ is the most abundant prostanoind in the inflammatory milieu, and it is one of the best known and most well-characterized prostanoinds in terms of immunomodulation. PGE₂ exerts its biological functions through four distinct G protein-coupled receptors called E prostanoind (EP) receptors, which are numbered EP1–4 (Woodward et al. 2011). Although PGE₂ has myriads of immunomodulatory effects and induces both pro- and anti-inflammatory effects, the immunosuppressive actions of PGE₂ to limit both the amplitude and duration of immune responses have been extensively studied and reported (Kalinski 2012; Agard et al. 2013). For example, PGE₂ suppresses macrophage phagocytosis (Aronoff et al. 2004; Lee et al. 2009; Serezani et al. 2012), restrains bacterial killing in alveolar macrophages by inhibiting NADPH oxidase (Serezani et al. 2007), exacerbates intrauterine group A *Streptococcal* infections (Mason et al. 2013), dampens antifungal immunity by inhibiting interferon regulatory factor 4 functions and interleukin-17 expression in

T cells (Valdez et al. 2012). Moreover, PGE₂ suppresses antiviral immunity through induction of type I interferon and apoptosis in macrophages (Coulombe et al. 2014), and blockade of PGE₂ signaling improves viral control (Chen et al. 2015). However, it has also been reported that PGE₂ induces resistance to HIV-1 infection by downregulation of the chemokine receptor CCR5 expression to suppress HIV-1 entry into macrophages (Thivierge et al. 1998). Several studies also demonstrate that PGE₂ plays an important role to inhibit *Mycobacterium tuberculosis* replication in vitro and in vivo (Chen et al. 2008; Kaul et al. 2012; Mayer-Barber et al. 2014).

Several lines of evidence indicate that PGs are involved in host defense by modulating HDP expression. Studies from insects have demonstrated that PGs induce the expression of humoral immune-associated genes, including HDP cecropin in the beet armyworm, *Spodoptera exigua* (Shrestha and Kim 2009). In another study on mosquito *Anopheles albimanus* has shown that PGE₂ reduces mRNA synthesis of HDP ambicin and attacin in cultured midguts and fat bodies, while enhancing the cecropin mRNA (Garcia Gil de Munoz et al. 2008). Studies have also demonstrated that PGD₂ induces human β -defensin (hBD)-3 production in human keratinocytes (Kanda et al. 2010), and one possible mechanism for the antimicrobial effects of the antimycotic drugs itraconazole and terbinafine hydrochloride could be to induce hBD-3 in keratinocytes by increasing PGD₂ release from keratinocytes (Kanda et al. 2011). Consistently, Bernard et al. also found that PGD₂ and 15-deoxy-D^{12,14}-PGJ₂ (a dehydration product of PGD₂) induces the production of hBD-2 and hBD-3 by human keratinocytes (Bernard and Gallo 2010). However, PGE₂ dramatically suppresses hBD-1 expression in human uterine epithelial cells, and also moderates TNF- α -induced hBD-2 expression in human uterine epithelial cells (Aronoff et al. 2008).

It is well-established that non-steroidal anti-inflammatory drugs (NSAIDs) block prostanoid synthesis by inhibiting COX enzymes and are widely used to treat both acute and chronic inflammation. Some evidence suggests that NSAID use is also linked to modulation of HDP expression. One report showed that the COX inhibitor etodolac enhanced hBD-2 mRNA levels in *Actinobacillus actinomycetemcomitans* infected human gingival epithelial cells (HGEC) (Noguchi et al. 2003). Since etodolac almost suppressed the production of PGE₂ by *A. actinomycetemcomitans* in HGEC, this result indicated that endogenous PGE₂ produced by *A. actinomycetemcomitans* in HGEC suppresses hBD-2 expression (Noguchi et al. 2003). In another report, Bernard et al. demonstrated a critical role for COX-2 in hBD production by human keratinocytes and treatment with a COX-2 inhibitor led to reduced antibacterial activity in these cells (Bernard and Gallo 2010). Interestingly, one recent report also describes that COX inhibitors aspirin or etoricoxib significantly suppress lactose/PBA-induced cathelicidin expression in the human epithelial cell line HT-29 (Cederlund et al. 2014). All these evidences suggest that prostanoid signaling is involved in the regulation of HDP expression.

6.2.2 Leukotrienes (LTs)

LT biosynthesis from free unesterified AA is catalyzed by a series of enzymes, starting from 5-lipoxygenase (5-LOX). Upon an increase in intracellular calcium, 5-LOX translocates to the nuclear membrane and associates with 5-LO-activating protein (FLAP) to promote dioxygenation and dehydration of AA (Dixon et al. 1990). This process gives rise to the unstable epoxide LTA_4 , the key intermediate in leukotriene biosynthesis, which is converted to LTB_4 through the action of LTA_4 hydrolase (Samuelsson and Funk 1989). LTA_4 can also be conjugated with GSH by LTC_4 synthase to produce LTC_4 , which constitutes the parent compound of the cysteinyl LTs (cys-LTs) also including LTD_4 and LTE_4 (Samuelsson et al. 1987). The biosynthesis of LTs is summarized in Fig. 6.2. LT production is cell type specific and largely limited to cells of the myeloid lineage. LT signaling is achieved through a family of GPCR. So far, it has been found that LTB_4 binds to two GPCRs, BLT1 and BLT2 with high and low affinity. Likewise, CysLT1, CysLT2




Fig. 6.2 Biosynthesis of leukotrienes (LTs) at the nuclear membrane. Upon certain stimuli, intracellular calcium level increases, leading to the translocation of 5-LOX from cytosol to the nuclear membrane (not depicted in figure). Free AA is presented to 5-LOX by the nuclear membrane integral protein 5-LO-activating protein (FLAP) and converted to LTA_4 , the key intermediate in LT biosynthesis. LTA_4 is further converted to LTB_4 by LTA_4H , and the released LTB_4 acts via its high affinity receptor BLT1 or low affinity receptor BLT2 on target cells. Meanwhile, LTA_4 can also be metabolized to LTC_4 by the integral membrane enzyme LTC_4S . LTC_4 is further transformed by extracellularly localized γ -glutamyl transpeptidase (GGT) to LTD_4 , and further into LTE_4 by membrane-bound dipeptidase (MBD). LTC_4 , LTD_4 and LTE_4 , together known as cys-LTs, can activate and bind to two main receptors CysLT1 and CysLT2 for their bioactivities

and a putative receptor for LTE₄ (CysLT3) have been reported to transduce cys-LT signaling (Back et al. 2011).

LTB₄ is best known for its role as a neutrophil chemoattractant, and cys-LTs are famous for their ability to induce bronchoconstriction in asthma (Peters-Golden and Henderson 2007). However, LTs are now recognized as important participants in the host response and they are produced at sites of infection by phagocytes, which promotes killing of microbes, including bacteria (Bailie et al. 1996; Mancuso et al. 1998, 2010; Serezani et al. 2005; Soares et al. 2013), mycobacteria (Peres et al. 2007; Tobin et al. 2010; Peres-Buzalaf et al. 2011; Tobin et al. 2012), fungi (Medeiros et al. 2008; Morato-Marques et al. 2011; Secatto et al. 2012, 2014), parasites (Talvani et al. 2002; Machado et al. 2005; Serezani et al. 2006; Morato et al. 2014; Canavaci et al. 2014) and virus (Flamand et al. 2004; Gosselin et al. 2005; Gaudreault and Gosselin 2008; Bertin et al. 2012).

Accumulating evidence has clearly demonstrated that LTs, particularly LTB₄, plays a significant role in the control of microbial infections through its ability to activate host immunity, for instance by promoting HDP release (Peters-Golden et al. 2005; Le Bel et al. 2014). A study on insects showed that LTB₄ induced expression of humoral immune-associated genes, including HDP cecropin in the beet armyworm, *S. exigua* (Shrestha and Kim 2009). Moreover, studies on human neutrophils demonstrated that LTB₄ induces the release of human HDP, including α -defensins, cathepsin G, elastase, lysozyme C, and LL-37 from human neutrophils via the BLT1 receptor (Wan et al. 2007; Flamand et al. 2007). Furthermore, it has been shown that *i.v.* injection of LTB₄ to monkey and human (Flamand et al. 2004, 2007) induces a dose-dependent plasmatic increase in α -defensins. Meanwhile, evidence has been provided that LTB₄-induced HDP production by neutrophils, transduced via BLT1, plays a role in LTB₄-mediated antiviral activity *in vitro* and *in vivo* (Gaudreault and Gosselin 2007, 2008). Recently, it was also reported that AA induces the release of HDPs (α -defensins and LL-37) from human neutrophils through metabolism into LTB₄ and the activation of BLT1 (Chouinard et al. 2013). All these studies further support the notion that LTB₄-induced HDPs play an important role in host defense.

6.2.3 Lipoxins (LXs)

In 1984, Serhan and colleagues discovered a new family of eicosanoids called lipoxins (LXs) (Serhan et al. 1984a, b). LXA₄ and LXB₄ are positional isomers that each possesses potent cellular and *in vivo* actions, whereas LXA₄ has been more widely studied for its functions. The LXs are generated from AA via sequential action of two or more LOXs during cell–cell interactions by transcellular biosynthetic routes that occur in inflammation and disease pathogenesis (Serhan 2005). Three transcellular pathways for biosynthesis of LXA₄ in human cells are depicted




Fig. 6.3 Transcellular biosynthesis of lipoxins (LXs). (I) 5-LOX in leukocytes converts AA to LTA₄, which is released from leukocytes and further transformed to LXA₄ via the enzyme 12-LOX in adherent platelets. (II) On mucosal surfaces, AA can be transformed via 15-LOX to 15S-hydroxy-eicosatetraenoic acid (15S-HETE), which is rapidly taken up by neutrophils and converted to LXA₄ via 5-LOX. (III) aspirin-acetylated COX-2 transforms AA to 15R-HETE, which is taken up by leukocytes and converted via 5-LOX to 15-epi-LXA₄, a product that is also called aspirin-triggered lipoxins (ATL)

in Fig. 6.3. The first pathway involves peripheral blood leukocyte–platelet interactions. The enzyme 5-LOX in leukocytes converts AA to LTA₄, which is released from leukocytes and further transformed by adherent platelets to LXA₄ via 12-LOX (Edenius et al. 1988; Romano and Serhan 1992). The second biosynthetic route is initiated at mucosal surfaces by 15-LOX that transforms AA to 15S-hydroxy-eicosatetraenoic acid (15S-HETE), which is rapidly taken up by neutrophils and subsequently converted via 5-LOX to LXA₄ (Serhan 1997). In addition to these two main routes, it has been discovered that aspirin-acetylated COX-2 can transform AA to 15R-HETE, which is taken up by leukocytes and converted via 5-LOX to 15-epi-LXA₄, also called aspirin-triggered lipoxins (ATL) (Claria and Serhan 1995).

LXs and ATL act at both temporal and spatially distinct sites from other eicosanoids produced during the course of inflammatory responses to actively participate in anti-inflammation and resolution of inflammation (Serhan 2005). LXs and

n-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid and docosahexaenoic acid-derived resolvins, protectins and maresins are collectively termed specialized proresolving mediators (SPM). Recent studies demonstrated that SPMs are temporally and differentially regulated during infections (Chiang et al. 2012), and they potently stimulate cessation of PMN infiltration and enhance macrophage uptake of apoptotic cells, debris and microbes (Serhan 2014), aiding a return to tissue homeostasis. Accumulated evidence demonstrated that SPM including LXA₄ play an important role in infectious diseases. Thus, it has been reported that LXA₄ displays protective effects on host defense against fungal pathogen *Cryptococcus neoformans* (Colby et al. 2015), parasite *Toxoplasma gondii* (Aliberti et al. 2002) and *Trypanosoma cruzi* (Molina-Berrios et al. 2013), respiratory viruses (Kim 1990; Shirey et al. 2014) and influenza A virus (Cilloniz et al. 2010), and cerebral malaria (Shryock et al. 2013). Moreover, LXA₄ exhibits beneficial effects on bacteria *Porphyromonas gingivalis*-induced periodontitis (Serhan et al. 2003) and LPS-induced preterm birth (Rinaldi et al. 2015). Interestingly, ATL combined with antibiotics protects mice from *Escherichia coli*-induced sepsis (Ueda et al. 2014). In contrast, LXA₄ seems to exert detrimental effects on *Mycobacterium tuberculosis* infection (Chen et al. 2008; Bafica et al. 2005).

Interestingly, it has been demonstrated that LXA₄ and other SPM also can regulate HDP expression. We have shown that resolvin E1 (RvE1) dampens LTB₄-induced human cathelicidin LL-37 release from human neutrophils via binding to BLT1 (Wan et al. 2011). On the other hand, ATL induces the expression of an antimicrobial peptide/protein called bactericidal permeability-increasing protein in epithelial cells (Canny et al. 2002). Campbell et al. concluded that generation of SPM in the resolution phase elicits the induction of “nonclassical” AMPs to accelerate return to homeostasis via continued bacterial killing, and inhibition of LPS signaling; meanwhile, SPMs can block and/or counteract the release of “classical” AMPs from leukocytes, dampening the proinflammatory signals (Campbell et al. 2011).

It is noteworthy that LXs act as agonists at specific GPCRs, in particular FPR2/ALX, to regulate cellular responses in inflammation and resolution (Fiore et al. 1994). Actually, FPR2/ALX binds both protein and lipid ligands that evoke opposing biological responses. For example, ALX mediates the proinflammatory actions of LL-37 (Wan et al. 2011) and the acute-phase protein serum amyloid A (SAA) (Bozinovski et al. 2012). In contrast, ALX also mediates the anti-inflammatory actions of the lipid LXA₄ (Fiore et al. 1994) and protein annexin A1 (AnxA1) (Perretti and D’Acquisto 2009). Actually, lipid and peptide ligands act with different affinities and bind to distinct pockets on the receptor, thus making a direct competition unlikely (Filep 2013). In one recent report, Cooray et al. identified that AnxA1, but not SAA, stimulated ALX homodimerization and activated the p38 MAPK/MAPKAPK/Hsp27 signaling cascade (Cooray et al. 2013).

6.3 HDPs and Eicosanoid Productions

Although first studied for their antimicrobial activity, HDPs are now widely recognized for their multifunctional roles in both the innate and adaptive immune responses. Their diverse immunomodulatory capabilities include the modulation of pro- and anti-inflammatory responses, chemoattraction, enhancement of extracellular and intracellular bacterial killing, cellular differentiation and activation of the innate and adaptive compartments, wound-healing, and modulation of autophagy as well as apoptosis and pyroptosis (Mansour et al. 2014). Increasing evidence demonstrate that HDPs also promote eicosanoid productions in various cell types to form a positive feedback loop between HDP and eicosanoid production, which plays an important role in several pathophysiological conditions.

6.3.1 Positive Feedback Loops Between HDPs and Eicosanoids

6.3.1.1 HDPs and LTB₄ in Host Defense

Human α -defensins, also known as human neutrophil peptides (HNP), are a major product of activated neutrophils. HNP types 1–4 are abundant in human neutrophils, constituting 5 % of all neutrophil proteins and 30–50 % of the total protein content of the azurophilic granules in neutrophils (Ganz et al. 1985). It has been shown that LTB₄ triggers the release of α -defensins from circulating neutrophils (Flamand et al. 2004; Gaudreault and Gosselin 2008; Flamand et al. 2007). Moreover, HNP promote LTB₄ production in human alveolar macrophages in a dose-dependent manner (Spencer et al. 2004), suggesting α -defensins and LTB₄ could interact through a positive feedback loop. In addition, our research group and others have demonstrated that LTB₄ also induces hCAP18/LL-37 release from neutrophils via the BLT1 receptor (Wan et al. 2007; Flamand et al. 2007). LL-37 is present at high concentrations as the inactive proform hCAP-18 in the secondary granules of neutrophils (Sorensen et al. 1997). Once hCAP18 is secreted from neutrophils, it is processed into the active LL-37 peptide by proteinase 3 that is present in the primary granules of these cells (Gudmundsson et al. 1996; Sorensen et al. 2001). Interestingly, we also identified that LL-37 induces intracellular calcium mobilization, activates p38 MAP kinase, promotes phosphorylation of cPLA₂ and translocation of 5-LOX, which promotes LTB₄ release from human neutrophils via the GPCR FPR2/ALX (Wan et al. 2007, 2011), and from human macrophages via P2X₇R (Wan et al. 2014), indicating that a positive feedback loop exists between cathelicidin and LTB₄ production as well.

Considering the importance of LTB₄-induced HDPs from neutrophils in antiviral activity *in vitro* and *in vivo* (Flamand et al. 2004, 2007; Gaudreault and Gosselin 2008), the positive feedback loop between LTB₄ and HDPs could be vital to

amplify the host antiviral activity. Recently, Chaves et al. provided evidence that P2X₇R activation in macrophages leads to LTB₄ formation, which is required for *L. amazonensis* elimination (Chaves et al. 2014). In our recent studies, we further demonstrate that LL-37 promotes LTB₄ production in human macrophage via P2X₇R (Wan et al. 2014) and that LL-37 enhances bacterial clearance by macrophages (Wan et al. 2014). Macrophages can also import LL-37 released from LTB₄-challenged neutrophils to promote intracellular bacterial clearance (Tang et al. 2015). All these evidences suggest the presence of positive feedback circuits between HDPs and LTB₄ that are important in host defense against various pathogens.

Intriguingly, we have also shown that anti-inflammatory lipid mediators LXA₄ and RvE1 might counteract the proinflammatory circuit between LL-37 and LTB₄ in human neutrophils by blocking the receptors FPR2/ALX and BLT1, respectively, that signal in a LTB₄/LL-37 positive feedback loop in neutrophils (Wan et al. 2011). It is noteworthy that both LTB₄ and LL-37 are involved in many chronic inflammatory diseases, such as atherosclerosis (Funk 2005; Qiu et al. 2006; Edfeldt et al. 2006), inflammatory bowel diseases (Hawthorne et al. 1992; Schaubert et al. 2006) and cancers (Satpathy et al. 2015; von Haussen et al. 2008). Therefore, it appears essential to interfere with and dampen LTB₄/LL-37 co-driven inflammatory responses.

6.3.1.2 HDPs and PGD₂/cys-LTs in Allergy

Human β -defensins (hBDs) are mainly produced by epithelia of several organs including skin, and participate in host defense by killing invading pathogens, as well as promoting both innate and adaptive immune responses (Yang et al. 1999). Among four hBDs identified in epithelium so far, hBD-1 is generally constitutively produced by various epithelial tissues such as those in the urogenital and respiratory tracts, and skin (Valore et al. 1998), whereas the expressions of hBD-2, hBD-3, and hBD-4 are inducible (Singh et al. 1998).

It has been reported that PGD₂ induces hBDs including hBD-2 and hBD-3 production in human keratinocytes (Kanda et al. 2010; Bernard and Gallo 2010). PGD₂ is the major prostaglandin produced by mast cells and is involved in allergic diseases such as asthma (Matsuoka et al. 2000). Interestingly, it has been reported that hBD-2 works as a chemotaxin for mast cells (Niyonsaba et al. 2002), and induces intracellular calcium mobilization, AA release and PGD₂ production in rat peritoneal mast cells via COX-1 (Niyonsaba et al. 2001; Kase et al. 2009). Furthermore, hBD-3 and hBD-4 also act on mast cells and enhances their chemotaxis and degranulation, which results in the release of PGD₂ (Chen et al. 2007). Moreover, cathelicidins can activate mast cells as well. For example, LL-37 was shown to induce intracellular calcium mobilization, AA release and PGD₂ production in rat peritoneal mast cells via COX-1 (Niyonsaba et al. 2001). Furthermore, rat cathelicidin rCRAMP and human cathelicidin LL-37 trigger generation and release of cys-LTs and other pro-inflammatory mediators in mast

cells (Babolewska et al. 2014; Babolewska and Brzezinska-Blaszczyk 2015). Work in our laboratory has also revealed that LL-37 induces synthesis and release of cys-LTs from human eosinophils via FPR2/ALX by enhancing cPLA₂ activity and inducing intracellular translocation and assembly of 5-LOX and LTC₄S at perinuclear locations and lipid bodies (Sun et al. 2013). In addition, we could observe that eosinophils from asthmatics express significantly higher hCAP18 protein levels compared with those from healthy subjects, and eosinophils isolated from asthmatics released more hCAP18 upon leukotriene stimulation than did cells from healthy subjects (Sun et al. 2013). Hence, this study suggested that a positive feedback loop also exists between leukotrienes and LL-37 in eosinophils, which might contribute to asthma progress. The results from all these studies indicate that the proinflammatory circuit between HDPs and eicosanoids in mast cells and eosinophils may be undesirable for the host during an antimicrobial process, and could be a potential therapeutic target for allergic diseases, such as asthma.

6.3.2 Other HDPs and Eicosanoid Production

One early study investigated the effects of two magainin peptides originally isolated from the skin of the African claw toad (*Xenopus laevis*) on eicosanoid synthesis by rat peritoneal macrophages stimulated with LPS and lipid A from *Salmonella*. The results showed that depending on the type of peptide used and on its concentration, these two magainin peptides exhibited different effects on LPS or lipid A-induced macrophage eicosanoid synthesis (TXB₂ and 6-keto-PGF_{1α}) (Matera et al. 1993). Another family of α -helical HDPs, pleurocidins, originate from fish and are structurally and functionally similar to cathelicidins (Cole et al. 1997; Patrzykat et al. 2003). Chiou et al. demonstrated that cecropin and pleurocidin induce gene expression of IL-1 β and COX-2 in a trout macrophage cell line (Peter Chiou et al. 2006), suggesting a proinflammatory role of pleurocidin in the vertebrate immune system. One recent report illustrated that pleurocidins activated human mast cells to induce intracellular calcium mobilization and production of cys-LTs and PGD₂ in human mast cells through the FPR2/ALX receptor (Pundir et al. 2014). Moreover, catestatin, a neuroendocrine antimicrobial peptide, can also activate human mast cells to induce intracellular calcium mobilization and the production of cys-LTs, PGD₂ and PGE₂ (Aung et al. 2011). Another report revealed that hBD-3 and LL-37 function as proinflammatory mediators to up-regulate COX-2 expression and PGE₂ synthesis in human gingival fibroblasts (Chotjumlong et al. 2010, 2013). Furthermore, we also identified that LL-37 elicited a biphasic release of eicosanoids in macrophages with early, Ca²⁺-dependent formation of LTB₄ and TXA₂ (measured as TXB₂) followed by a late peak of TXA₂ (measured as TXB₂), generated via induction of COX-2 by internalized LL-37 (Wan et al. 2014). Importantly, our findings provide evidence that LL-37 is an endogenous regulator of eicosanoid-dependent inflammatory responses in vivo, since intraperitoneal injection of mice with murine cathelicidin-related antimicrobial peptide (mCRAMP) induces significantly higher levels of LTB₄ and




Fig. 6.4 The crosstalk between LL-37, a human HDP, and eicosanoids in leukocytes. Inflammation is induced (e.g., by microbes), and neutrophils are recruited to the sites of inflammation guided by chemoattractants, such as LTB_4 . LTB_4 can trigger the release of hCAP18/LL-37 via BLT1. The released LL-37 conversely induces LTB_4 production from neutrophils via FPR2/ALX, or from macrophages via P2X₇R, by triggering intracellular calcium mobilization, activating p38 MAP kinase, promoting phosphorylation of cPLA₂ and translocation of 5-LOX. Similarly, the released LL-37 also induces LTB_4 production from macrophages. Therefore, there is a positive feedback loop between LL-37 and LTB_4 production in leukocytes, which can be blocked by the anti-inflammatory lipid mediators LXA₄ and RvE₁ by competition with LL-37 or LTB_4 for binding at FPR2/ALX or BLT1, respectively. Moreover, the neutrophil-released LL-37 can also be taken up by macrophages, leading to further eicosanoid production such as TXA₂ or facilitated intracellular bacterial killing

TXA₂ in mouse ascites rich in macrophages. Conversely, cathelicidin-deficient (Clnp^{-/-}) mice produce much less LTB_4 and TXB₂ *in vivo* in response to TNF- α compared with control mice (Wan et al. 2014). Additionally, we also found that LL-37 induces angiogenesis via PGE₂–EP3 signaling in endothelial cells, and mCRAMP also induced prostaglandin-dependent angiogenesis *in vivo*, which could be blocked by aspirin (Salvado et al. 2013).

6.4 Conclusion

As two important components in innate immunity and inflammation, plenty of studies on HDPs and eicosanoids have been undertaken. Accumulated evidence demonstrates that HDPs not only kill pathogens directly, but also possess potent immunoregulatory activities including regulation of eicosanoid production. Meanwhile, eicosanoids participate in host defense via various mechanisms, one of

which is to modulate HDP production. The crosstalk between these two families of molecules has been concluded in Fig. 6.4. Considering the involvement of these two families of peptides and lipids in several pathophysiological situations, such as infections and allergy, intervention in positive cross-signaling loops has become a potential strategy for treatments against infection, allergy, and other inflammatory diseases.

Acknowledgments Work in the authors' laboratory was supported by the Swedish Research Council (10350, Linneus Grant CERIC), the Cardiovascular Program, Thematic Center for Inflammation and Stiftelsen Clas Groschinskys Minnesfond. JZH is supported by a Distinguished Professor Award from Karolinska Institutet and XT by a Ph.D. stipend from China Scholarship Council.

References

- Agard M, Asakrah S, Morici LA (2013) PGE(2) suppression of innate immunity during mucosal bacterial infection. *Front Cell Infect Microbiol* 3:45
- Aliberti J, Serhan C, Sher A (2002) Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in *Toxoplasma gondii* infection. *J Exp Med* 196(9):1253–1262
- Aronoff DM, Canetti C, Peters-Golden M (2004) Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. *J Immunol* 173(1):559–565
- Aronoff DM et al (2008) Misoprostol impairs female reproductive tract innate immunity against *Clostridium sordellii*. *J Immunol* 180(12):8222–8230
- Aung G et al (2011) Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. *Immunology* 132(4):527–539
- Babolewska E, Brzezinska-Blaszczyk E (2015) Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response. *Cell Immunol* 293(2):67–73
- Babolewska E, Pietrzak A, Brzezinska-Blaszczyk E (2014) Cathelicidin rCRAMP stimulates rat mast cells to generate cysteinyl leukotrienes, synthesize TNF and migrate: involvement of PLC/A2, PI3 K and MAPK signaling pathways. *Int Immunol* 26(11):637–646
- Back M et al (2011) International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. *Pharmacol Rev* 63(3):539–584
- Bafica A et al (2005) Host control of *Mycobacterium tuberculosis* is regulated by 5-lipoxygenase-dependent lipoxin production. *J Clin Invest* 115(6):1601–1606
- Bailie MB et al (1996) Leukotriene-deficient mice manifest enhanced lethality from *Klebsiella pneumoniae* in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J Immunol* 157(12):5221–5224
- Bernard JJ, Gallo RL (2010) Cyclooxygenase-2 enhances antimicrobial peptide expression and killing of *Staphylococcus aureus*. *J Immunol* 185(11):6535–6544
- Bertin J et al (2012) Leukotrienes inhibit early stages of HIV-1 infection in monocyte-derived microglia-like cells. *J Neuroinflamm* 9:55
- Bozinovski S et al (2012) Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. *Proc Natl Acad Sci U S A* 109(3):935–940

- Campbell EL, Serhan CN, Colgan SP (2011) Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. *J Immunol* 187(7):3475–3481
- Canavaci AM et al (2014) The acute phase of *Trypanosoma cruzi* infection is attenuated in 5-lipoxygenase-deficient mice. *Mediators Inflamm* 2014:893634
- Canny G et al (2002) Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. *Proc Natl Acad Sci U S A* 99(6):3902–3907
- Cederlund A et al (2014) Label-free quantitative mass spectrometry reveals novel pathways involved in LL-37 expression. *J Innate Immun* 6(3):365–376
- Chaves MM et al (2014) Leukotriene B4 modulates P2X7 receptor-mediated *Leishmania amazonensis* elimination in murine macrophages. *J Immunol* 192(10):4765–4773
- Chen X et al (2007) Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. *Eur J Immunol* 37(2):434–444
- Chen M et al (2008) Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. *J Exp Med* 205(12):2791–2801
- Chen JH et al (2015) Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. *Nat Med* 21(4):327–334
- Chiang N et al (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. *Nature* 484(7395):524–528
- Chotjumlong P et al (2010) Human beta-defensin-3 up-regulates cyclooxygenase-2 expression and prostaglandin E2 synthesis in human gingival fibroblasts. *J Periodontol Res* 45(4):464–470
- Chotjumlong P et al (2013) Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37. *J Innate Immun* 5(1):72–83
- Chouinard F et al (2013) 2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against *E. coli*, *S. aureus*, HSV-1, and RSV. *J Leukoc Biol* 93(2):267–276
- Cilloniz C et al (2010) Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. *J Virol* 84(15):7613–7624
- Claria J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. *Proc Natl Acad Sci U S A* 92(21):9475–9479
- Colby JK et al (2015) Differences in lung *Cryptococcus neoformans* burden after infection are associated with lipoxin signaling. *Am J Respir Cell Mol Biol*
- Cole AM, Weis P, Diamond G (1997) Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder. *J Biol Chem* 272(18):12008–12013
- Cooray SN et al (2013) Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. *Proc Natl Acad Sci U S A* 110(45):18232–18237
- Coulombe F et al (2014) Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. *Immunity* 40(4):554–568
- Dennis EA, Norris PC (2015) Eicosanoid storm in infection and inflammation. *Nat Rev Immunol*
- Dennis EA et al (2011) Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem Rev* 111(10):6130–6185
- Dixon RA et al (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. *Nature* 343(6255):282–284
- Edenius C, Haeggstrom J, Lindgren JA (1988) Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. *Biochem Biophys Res Commun* 157(2):801–807
- Edfeldt K et al (2006) Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. *Arterioscler Thromb Vasc Biol* 26(7):1551–1557
- Filep JG (2013) Biasing the lipoxin A4/formyl peptide receptor 2 pushes inflammatory resolution. *Proc Natl Acad Sci U S A* 110(45):18033–18034

- Fiore S et al (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. *J Exp Med* 180(1):253–260
- Flamand L et al (2004) Release of anti-HIV mediators after administration of leukotriene B4 to humans. *J Infect Dis* 189(11):2001–2009
- Flamand L, Tremblay MJ, Borgeat P (2007) Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. *J Immunol* 178(12):8036–8045
- Fujishima H et al (1999) Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. *Proc Natl Acad Sci U S A* 96(9):4803–4807
- Funk CD (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. *Nat Rev Drug Discov* 4(8):664–672
- Ganz T et al (1985) Defensins. Natural peptide antibiotics of human neutrophils. *J Clin Invest* 76(4):1427–1435
- Garcia Gil de Munoz FL et al (2008) Prostaglandin E2 modulates the expression of antimicrobial peptides in the fat body and midgut of *Anopheles albimanus*. *Arch Insect Biochem Physiol* 68(1):14–25
- Gaudreault E, Gosselin J (2007) Leukotriene B4-mediated release of antimicrobial peptides against cytomegalovirus is BLT1 dependent. *Viral Immunol* 20(3):407–420
- Gaudreault E, Gosselin J (2008) Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. *J Immunol* 180(9):6211–6221
- Gijon MA et al (2000) Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. *J Biol Chem* 275(26):20146–20156
- Gosselin J, Borgeat P, Flamand L (2005) Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation. *J Immunol* 174(3):1587–1593
- Gudmundsson GH et al (1996) The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. *Eur J Biochem* 238(2):325–332
- Haeggstrom JZ, Funk CD (2011) Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. *Chem Rev* 111(10):5866–5898
- Harizi H, Gualde N (2005) The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. *Tissue Antigens* 65(6):507–514
- Hawthorne AB et al (1992) Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. *Gut* 33(4):513–517
- Hirata T, Narumiya S (2012) Prostanoids as regulators of innate and adaptive immunity. *Adv Immunol* 116:143–174
- Hwang J et al (2013) An entomopathogenic bacterium, *Xenorhabdus nematophila*, suppresses expression of antimicrobial peptides controlled by Toll and Imd pathways by blocking eicosanoid biosynthesis. *Arch Insect Biochem Physiol* 83(3):151–169
- Kalinski P (2012) Regulation of immune responses by prostaglandin E2. *J Immunol* 188(1):21–28
- Kanda N, Ishikawa T, Watanabe S (2010) Prostaglandin D2 induces the production of human beta-defensin-3 in human keratinocytes. *Biochem Pharmacol* 79(7):982–989
- Kanda N et al (2011) The antimycotic drugs itraconazole and terbinafine hydrochloride induce the production of human beta-defensin-3 in human keratinocytes. *Immunobiology* 216(4):497–504
- Kase K et al (2009) Inhibitory action of roxithromycin on histamine release and prostaglandin D2 production from beta-defensin 2-stimulated mast cells. *Int J Mol Med* 23(3):337–340
- Kaul V et al (2012) An important role of prostanoid receptor EP2 in host resistance to *Mycobacterium tuberculosis* infection in mice. *J Infect Dis* 206(12):1816–1825
- Kim SJ (1990) Elevated formation of lipoxins in viral antibody-positive rat alveolar macrophages. *Am J Respir Cell Mol Biol* 3(2):113–118
- Le Bel M, Brunet A, Gosselin J (2014) Leukotriene B4, an endogenous stimulator of the innate immune response against pathogens. *J Innate Immun* 6(2):159–168

- Lee SP et al (2009) Crosstalk between prostaglandin E2 and leukotriene B4 regulates phagocytosis in alveolar macrophages via combinatorial effects on cyclic AMP. *J Immunol* 182(1):530–537
- Leslie CC (2015) Cytosolic phospholipase A2: physiological function and role in disease. *J Lipid Res*
- Machado ER et al (2005) Leukotrienes play a role in the control of parasite burden in murine strongyloidiasis. *J Immunol* 175(6):3892–3899
- Mancuso P et al (1998) 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of *Klebsiella pneumoniae*. *Infect Immun* 66(11):5140–5146
- Mancuso P et al (2010) Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. *Infect Immun* 78(5):2264–2271
- Mansour SC, Pena OM, Hancock RE (2014) Host defense peptides: front-line immunomodulators. *Trends Immunol* 35(9):443–450
- Mason KL et al (2013) Intrauterine group A streptococcal infections are exacerbated by prostaglandin E2. *J Immunol* 191(5):2457–2465
- Matera G et al (1993) Effects of two magainin peptides on eicosanoid release from rat peritoneal macrophages. *Antimicrob Agents Chemother* 37(3):393–397
- Matsuoka T et al (2000) Prostaglandin D2 as a mediator of allergic asthma. *Science* 287(5460):2013–2017
- Mayer-Barber KD et al (2014) Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. *Nature* 511(7507):99–103
- Medeiros AI et al (2008) Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. *J Immunol* 181(12):8544–8551
- Miller JS, Nguyen T, Stanley-Samuelson DW (1994) Eicosanoids mediate insect nodulation responses to bacterial infections. *Proc Natl Acad Sci U S A* 91(26):12418–12422
- Molina-Berrios A et al (2013) Protective role of acetylsalicylic acid in experimental *Trypanosoma cruzi* infection: evidence of a 15-epi-lipoxin A(4)-mediated effect. *PLoS Negl Trop Dis* 7(4):e2173
- Morato CI et al (2014) Essential role of leukotriene B4 on *Leishmania* (*Viannia*) *braziliensis* killing by human macrophages. *Microbes Infect* 16(11):945–953
- Morato-Marques M et al (2011) Leukotrienes target F-actin/cofilin-1 to enhance alveolar macrophage anti-fungal activity. *J Biol Chem* 286(33):28902–28913
- Morishima I et al (1997) Eicosanoids mediate induction of immune genes in the fat body of the silkworm, *Bombyx mori*. *FEBS Lett* 419(1):83–86
- Niyonsaba F et al (2001) Evaluation of the effects of peptide antibiotics human beta-defensins-1/2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. *Eur J Immunol* 31(4):1066–1075
- Niyonsaba F et al (2002) Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. *Int Immunol* 14(4):421–426
- Noguchi T et al (2003) Syntheses of prostaglandin E2 and E-cadherin and gene expression of beta-defensin-2 by human gingival epithelial cells in response to *Actinobacillus actinomycescomitans*. *Inflammation* 27(6):341–349
- Patrzykat A et al (2003) Novel antimicrobial peptides derived from flatfish genes. *Antimicrob Agents Chemother* 47(8):2464–2470
- Peres CM et al (2007) Inhibition of leukotriene biosynthesis abrogates the host control of *Mycobacterium tuberculosis*. *Microbes Infect* 9(4):483–489
- Peres-Buzalaf C et al (2011) Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins. *Prostaglandins Leukot Essent Fatty Acids* 85(2):75–81
- Perretti M, D'Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. *Nat Rev Immunol* 9(1):62–70
- Peter Chiou P et al (2006) Effects of linear cationic alpha-helical antimicrobial peptides on immune-relevant genes in trout macrophages. *Dev Comp Immunol* 30(9):797–806

- Peters-Golden M, Henderson WR Jr (2007) Leukotrienes. *N Engl J Med* 357(18):1841–1854
- Peters-Golden M et al (2005) Leukotrienes: underappreciated mediators of innate immune responses. *J Immunol* 174(2):589–594
- Pundir P et al (2014) Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. *Mucosal Immunol* 7(1):177–187
- Qiu H et al (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. *Proc Natl Acad Sci U S A* 103(21):8161–8166
- Rinaldi SF et al (2015) 15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth. *Mol Hum Reprod* 21(4):359–368
- Romano M, Serhan CN (1992) Lipoxin generation by permeabilized human platelets. *Biochemistry* 31(35):8269–8277
- Salvado MD et al (2013) Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. *Arterioscler Thromb Vasc Biol* 33(8):1965–1972
- Samuelsson B, Funk CD (1989) Enzymes involved in the biosynthesis of leukotriene B4. *J Biol Chem* 264(33):19469–19472
- Samuelsson B et al (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. *Science* 237(4819):1171–1176
- Satpathy SR et al (2015) Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth. *Nat Commun* 6:7064
- Schauber J et al (2006) Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. *Eur J Gastroenterol Hepatol* 18(6):615–621
- Secatto A et al (2012) 5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection. *PLoS ONE* 7(3):e31701
- Secatto A et al (2014) The leukotriene B(4)/BLT(1) axis is a key determinant in susceptibility and resistance to histoplasmosis. *PLoS ONE* 9(1):e85083
- Serezani CH et al (2005) Leukotrienes enhance the bactericidal activity of alveolar macrophages against *Klebsiella pneumoniae* through the activation of NADPH oxidase. *Blood* 106(3):1067–1075
- Serezani CH et al (2006) Leukotrienes are essential for the control of *Leishmania amazonensis* infection and contribute to strain variation in susceptibility. *J Immunol* 177(5):3201–3208
- Serezani CH et al (2007) Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. *Am J Respir Cell Mol Biol* 37(5):562–570
- Serezani CH et al (2012) PTEN directly activates the actin depolymerization factor cofilin-1 during PGE2-mediated inhibition of phagocytosis of fungi. *Sci Signal* 5(210):ra12
- Serhan CN (1997) Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? *Prostaglandins* 53(2):107–137
- Serhan CN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. *Prostaglandins Leukot Essent Fatty Acids* 73(3–4):141–162
- Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. *Nature* 510(7503):92–101
- Serhan CN, Hamberg M, Samuelsson B (1984a) Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. *Biochem Biophys Res Commun* 118(3):943–949
- Serhan CN, Hamberg M, Samuelsson B (1984b) Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. *Proc Natl Acad Sci U S A* 81(17):5335–5339
- Serhan CN et al (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. *J Immunol* 171(12):6856–6865
- Shirey KA et al (2014) Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. *Mucosal Immunol* 7(3):549–557

- Shrestha S, Kim Y (2009) Various eicosanoids modulate the cellular and humoral immune responses of the beet armyworm, *Spodoptera exigua*. *Biosci Biotechnol Biochem* 73(9):2077–2084
- Shryock N et al (2013) Lipoxin A(4) and 15-epi-lipoxin A(4) protect against experimental cerebral malaria by inhibiting IL-12/IFN-gamma in the brain. *PLoS ONE* 8(4):e61882
- Singh PK et al (1998) Production of beta-defensins by human airway epithelia. *Proc Natl Acad Sci U S A* 95(25):14961–14966
- Smith WL, Urade Y, Jakobsson PJ (2011) Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. *Chem Rev* 111(10):5821–5865
- Soares EM et al (2013) Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent *Streptococcus pyogenes*. *J Immunol* 190(4):1614–1622
- Sorensen O et al (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. *Blood* 90(7):2796–2803
- Sorensen OE et al (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood* 97(12):3951–3959
- Spencer LT et al (2004) Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. *Am J Physiol Lung Cell Mol Physiol* 286(3):L514–L520
- Stanley-Samuels DW et al (1991) Insect immune response to bacterial infection is mediated by eicosanoids. *Proc Natl Acad Sci U S A* 88(3):1064–1068
- Stanley-Samuels D et al (1997) Eicosanoids mediate microaggregation and nodulation responses to bacterial infections in black cutworms, *Agrotis ipsilon*, and true armyworms, *Pseudaletia unipuncta*. *J Insect Physiol* 43(2):125–133
- Sun SC, Faye I (1995) Transcription of immune genes in the giant silkworm, *Hyalophora cecropia*, is augmented by H₂O₂ and diminished by thiol reagents. *Eur J Biochem* 231(1):93–98
- Sun J et al (2013) The antimicrobial peptide LL-37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils—implications for asthma. *Allergy* 68(3):304–311
- Suram S et al (2006) Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor. *J Biol Chem* 281(9):5506–5514
- Suram S et al (2010) Pathways regulating cytosolic phospholipase A2 activation and eicosanoid production in macrophages by *Candida albicans*. *J Biol Chem* 285(40):30676–30685
- Suram S et al (2013) Cytosolic phospholipase A(2)alpha and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation. *PLoS ONE* 8(7):e69002
- Talvani A et al (2002) Leukotriene B(4) induces nitric oxide synthesis in *Trypanosoma cruzi*-infected murine macrophages and mediates resistance to infection. *Infect Immun* 70(8):4247–4253
- Tang X et al (2015) P2X7 Receptor regulates internalization of antimicrobial peptide LL-37 by human macrophages that promotes intracellular pathogen clearance. *J Immunol*
- Thivierge M et al (1998) Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. *Blood* 92(1):40–45
- Tobin DM et al (2010) The It4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. *Cell* 140(5):717–730
- Tobin DM et al (2012) Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. *Cell* 148(3):434–446
- Ueda T et al (2014) Combination therapy of 15-epi-lipoxin A4 with antibiotics protects mice from *Escherichia coli*-induced sepsis*. *Crit Care Med* 42(4):e288–e295
- Valdez PA et al (2012) Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. *Immunity* 36(4):668–679
- Valore EV et al (1998) Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. *J Clin Invest* 101(8):1633–1642
- von Haussen J et al (2008) The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. *Lung Cancer* 59(1):12–23

- Wan M et al (2007) Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. *FASEB J* 21(11):2897–2905
- Wan M et al (2011) Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. *FASEB J* 25(5):1697–1705
- Wan M et al (2014a) Cathelicidin LL-37 induces time-resolved release of LTB4 and TXA2 by human macrophages and triggers eicosanoid generation in vivo. *FASEB J* 28(8):3456–3467
- Wan M et al (2014b) Antimicrobial peptide LL-37 promotes bacterial phagocytosis by human macrophages. *J Leukoc Biol* 95(6):971–981
- Woodward DF, Jones RL, Narumiya S (2011) International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. *Pharmacol Rev* 63(3):471–538
- Yajima M et al (2003) A newly established in vitro culture using transgenic *Drosophila* reveals functional coupling between the phospholipase A2-generated fatty acid cascade and lipopolysaccharide-dependent activation of the immune deficiency (*imd*) pathway in insect immunity. *Biochem J* 371(Pt 1):205–210
- Yang D et al (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* 286(5439):525–528
- Zaslouf M (2002) Antimicrobial peptides of multicellular organisms. *Nature* 415(6870):389–395